Failure to seroconvert after three doses of inactivated COVID-19 vaccines in a patient co-infected with HBV and HIV: A case report
In the global context of the COVID-19 pandemic, the overall benefits of getting any COVID-19 vaccine approved by the World Health Organization for emergency use outweigh the potential risks, even in people with weakened immune systems, including people living with HIV (PLWH). At present, there are n...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Book |
| Published: |
Taylor & Francis Group,
2022-11-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_833543f4a14b4d35a07c8d7bec9cb74b | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Guang Zeng |e author |
| 700 | 1 | 0 | |a Jie Tang |e author |
| 700 | 1 | 0 | |a Shuidong Feng |e author |
| 700 | 1 | 0 | |a Liumei Xu |e author |
| 700 | 1 | 0 | |a Xiaohui Wang |e author |
| 700 | 1 | 0 | |a Zhengrong Yang |e author |
| 245 | 0 | 0 | |a Failure to seroconvert after three doses of inactivated COVID-19 vaccines in a patient co-infected with HBV and HIV: A case report |
| 260 | |b Taylor & Francis Group, |c 2022-11-01T00:00:00Z. | ||
| 500 | |a 2164-5515 | ||
| 500 | |a 2164-554X | ||
| 500 | |a 10.1080/21645515.2022.2110799 | ||
| 520 | |a In the global context of the COVID-19 pandemic, the overall benefits of getting any COVID-19 vaccine approved by the World Health Organization for emergency use outweigh the potential risks, even in people with weakened immune systems, including people living with HIV (PLWH). At present, there are no reports of HIV/hepatitis B virus (HBV) co-infected patients receiving a booster dose of the inactivated COVID-19 vaccine. Here, we describe a patient with HIV/HBV co-infection who did not seroconvert to three doses of the inactivated COVID-19 vaccine. | ||
| 546 | |a EN | ||
| 690 | |a hiv/hbv co-infection | ||
| 690 | |a people living with hiv | ||
| 690 | |a inactivated covid-19 vaccine | ||
| 690 | |a spike receptor binding domain igg (s-rbd-igg) antibody | ||
| 690 | |a cd4+t cell count | ||
| 690 | |a viral load (vl) | ||
| 690 | |a Immunologic diseases. Allergy | ||
| 690 | |a RC581-607 | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Human Vaccines & Immunotherapeutics, Vol 18, Iss 6 (2022) | |
| 787 | 0 | |n http://dx.doi.org/10.1080/21645515.2022.2110799 | |
| 787 | 0 | |n https://doaj.org/toc/2164-5515 | |
| 787 | 0 | |n https://doaj.org/toc/2164-554X | |
| 856 | 4 | 1 | |u https://doaj.org/article/833543f4a14b4d35a07c8d7bec9cb74b |z Connect to this object online. |